CR20150572A - Métodos para tratar la psoriasis utilizando un anticuerpo ant-il-23 - Google Patents
Métodos para tratar la psoriasis utilizando un anticuerpo ant-il-23Info
- Publication number
- CR20150572A CR20150572A CR20150572A CR20150572A CR20150572A CR 20150572 A CR20150572 A CR 20150572A CR 20150572 A CR20150572 A CR 20150572A CR 20150572 A CR20150572 A CR 20150572A CR 20150572 A CR20150572 A CR 20150572A
- Authority
- CR
- Costa Rica
- Prior art keywords
- methods
- treat psoriasis
- products
- antibody
- psoriasis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361789777P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/018293 WO2014149425A1 (en) | 2013-03-15 | 2014-02-25 | Methods for treating psoriasis using an anti-il-23 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20150572A true CR20150572A (es) | 2016-04-25 |
Family
ID=50336511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20150572A CR20150572A (es) | 2013-03-15 | 2015-10-15 | Métodos para tratar la psoriasis utilizando un anticuerpo ant-il-23 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20160060337A1 (enExample) |
| EP (2) | EP2968488A1 (enExample) |
| JP (4) | JP2016517408A (enExample) |
| KR (1) | KR20150128858A (enExample) |
| CN (1) | CN105209064A (enExample) |
| AP (1) | AP2015008803A0 (enExample) |
| AU (3) | AU2014238148A1 (enExample) |
| CA (1) | CA2906382A1 (enExample) |
| CL (1) | CL2015002723A1 (enExample) |
| CR (1) | CR20150572A (enExample) |
| EA (1) | EA201591581A1 (enExample) |
| HK (1) | HK1219425A1 (enExample) |
| IL (2) | IL241342A0 (enExample) |
| PH (2) | PH12015502129A1 (enExample) |
| SG (2) | SG10201804954UA (enExample) |
| TN (1) | TN2015000403A1 (enExample) |
| WO (1) | WO2014149425A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2635601T (pt) | 2010-11-04 | 2016-09-27 | Boehringer Ingelheim Int | Anticorpos anti-il-23 |
| EP4039275A1 (en) | 2012-05-03 | 2022-08-10 | Boehringer Ingelheim International GmbH | Anti-il-23p19 antibodies |
| US10507241B2 (en) | 2014-07-24 | 2019-12-17 | Boehringer Ingelheim International Gmbh | Biomarkers useful in the treatment of IL-23A related diseases |
| EA039598B9 (ru) | 2014-09-03 | 2022-03-10 | Бёрингер Ингельхайм Интернациональ Гмбх | Соединение, нацеленное на ил-23а и фно-альфа, и его применение |
| IL307578A (en) | 2015-02-04 | 2023-12-01 | Boehringer Ingelheim Int | Methods of treating inflammatory diseases |
| AU2017241776B2 (en) * | 2016-03-29 | 2024-06-20 | Janssen Biotech, Inc. | Treating psoriasis with increased interval dosing of anti-IL12 and/or -23 antibody |
| AU2017250583A1 (en) * | 2016-04-15 | 2018-08-16 | Boehringer Ingelheim International Gmbh | Methods of treating inflammatory diseases |
| WO2020016838A2 (en) * | 2018-07-18 | 2020-01-23 | Janssen Biotech, Inc. | Sustained response predictors after treatment with anti-il23 specific antibody |
| BR112021008582A8 (pt) * | 2018-11-05 | 2023-02-07 | Merck Sharp & Dohme | Regime de dosagem de anticorpo anti-tigit para tratamento de câncer |
| WO2020188466A1 (en) * | 2019-03-18 | 2020-09-24 | Janssen Biotech, Inc. | Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| PE20000183A1 (es) | 1997-07-25 | 2000-03-11 | Schering Corp | Citoquinas de mamiferos y reactivos relacionados |
| EP3501537A1 (en) | 2005-06-30 | 2019-06-26 | Janssen Biotech, Inc. | Anti-il23 antibodies, compositions, methods and uses |
| WO2007024846A2 (en) | 2005-08-25 | 2007-03-01 | Eli Lilly And Company | Anit-il-23 antibiodies |
| US20070050011A1 (en) | 2005-08-26 | 2007-03-01 | Medlogics Device Corporation | Lumen-supporting stents and methods for creating lumen-supporting stents with various open/closed designs |
| SG165322A1 (en) | 2005-08-31 | 2010-10-28 | Schering Corp | Engineered anti-il-23 antibodies |
| CN101389769A (zh) * | 2005-12-28 | 2009-03-18 | 森托科尔公司 | 用于评价和治疗银屑病及相关疾病的标记与方法 |
| JP5193881B2 (ja) | 2005-12-29 | 2013-05-08 | セントカー・インコーポレーテツド | ヒト抗ｉｌ−２３抗体、組成物、方法および用途 |
| AU2007260787A1 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc | IL-17 and IL-23 antagonists and methods of using the same |
| BRPI0807710B1 (pt) | 2007-02-23 | 2021-12-14 | Merck Sharp & Dohme Corp | Anticorpos que se ligam a il-23p19 e il-23 humana, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira microbiana, método de produção de um polipeptídeo e composição farmacêutica |
| US20100111966A1 (en) * | 2007-02-23 | 2010-05-06 | Schering Corporation | Engineered anti-il-23p19 antibodies |
| AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
| WO2009082624A2 (en) | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| JP2011515404A (ja) * | 2008-03-18 | 2011-05-19 | アボット・ラボラトリーズ | 乾癬を治療するための方法 |
| CN102113185B (zh) | 2008-06-30 | 2013-12-18 | 百得有限公司 | 用于电动工具的线保护器 |
| WO2010027766A1 (en) | 2008-08-27 | 2010-03-11 | Schering Corporation | Lyophilized formulatons of engineered anti-il-23p19 antibodies |
| JP2012522749A (ja) | 2009-04-01 | 2012-09-27 | グラクソ グループ リミテッド | 抗ｉｌ−２３免疫グロブリン |
| EP2435480A1 (en) | 2009-05-27 | 2012-04-04 | Ablynx N.V. | Biparatopic protein constructs directed against il-23 |
| SG179135A1 (en) * | 2009-09-14 | 2012-05-30 | Abbott Lab | Methods for treating psoriasis |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| EA201891433A3 (ru) | 2010-01-15 | 2019-02-28 | Кирин-Эмджен, Инк. | Состав антитела и терапевтические режимы |
| WO2012009760A1 (en) | 2010-07-20 | 2012-01-26 | Cephalon Australia Pty Ltd | Anti-il-23 heterodimer specific antibodies |
| AU2011311965A1 (en) * | 2010-10-06 | 2013-03-28 | Abbvie Inc. | Methods for treating psoriasis |
| WO2012045848A1 (en) * | 2010-10-08 | 2012-04-12 | Novartis Ag | Methods of treating psoriasis using il-17 antagonists |
| PT2635601T (pt) | 2010-11-04 | 2016-09-27 | Boehringer Ingelheim Int | Anticorpos anti-il-23 |
-
2014
- 2014-02-25 KR KR1020157027833A patent/KR20150128858A/ko not_active Ceased
- 2014-02-25 HK HK16107479.7A patent/HK1219425A1/zh unknown
- 2014-02-25 EP EP14711352.6A patent/EP2968488A1/en not_active Withdrawn
- 2014-02-25 CN CN201480015797.0A patent/CN105209064A/zh active Pending
- 2014-02-25 JP JP2016500381A patent/JP2016517408A/ja active Pending
- 2014-02-25 AP AP2015008803A patent/AP2015008803A0/xx unknown
- 2014-02-25 SG SG10201804954UA patent/SG10201804954UA/en unknown
- 2014-02-25 WO PCT/US2014/018293 patent/WO2014149425A1/en not_active Ceased
- 2014-02-25 CA CA2906382A patent/CA2906382A1/en not_active Abandoned
- 2014-02-25 AU AU2014238148A patent/AU2014238148A1/en not_active Abandoned
- 2014-02-25 EA EA201591581A patent/EA201591581A1/ru unknown
- 2014-02-25 US US14/776,222 patent/US20160060337A1/en not_active Abandoned
- 2014-02-25 SG SG11201507482UA patent/SG11201507482UA/en unknown
- 2014-02-25 EP EP19206477.2A patent/EP3689369A1/en not_active Withdrawn
-
2015
- 2015-09-09 IL IL241342A patent/IL241342A0/en unknown
- 2015-09-09 TN TN2015000403A patent/TN2015000403A1/en unknown
- 2015-09-15 PH PH12015502129A patent/PH12015502129A1/en unknown
- 2015-09-15 CL CL2015002723A patent/CL2015002723A1/es unknown
- 2015-10-15 CR CR20150572A patent/CR20150572A/es unknown
-
2019
- 2019-01-11 AU AU2019200206A patent/AU2019200206A1/en not_active Abandoned
- 2019-09-24 JP JP2019172758A patent/JP2020063237A/ja active Pending
- 2019-10-10 US US16/598,714 patent/US20200277368A1/en not_active Abandoned
- 2019-11-28 PH PH12019502700A patent/PH12019502700A1/en unknown
-
2020
- 2020-06-03 IL IL275093A patent/IL275093A/en unknown
- 2020-11-18 AU AU2020270495A patent/AU2020270495A1/en not_active Abandoned
-
2021
- 2021-03-29 JP JP2021054632A patent/JP2021102644A/ja active Pending
-
2022
- 2022-01-13 US US17/574,980 patent/US20220135668A1/en not_active Abandoned
- 2022-11-02 JP JP2022175999A patent/JP2023011815A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20200277368A1 (en) | 2020-09-03 |
| EP3689369A1 (en) | 2020-08-05 |
| JP2021102644A (ja) | 2021-07-15 |
| IL241342A0 (en) | 2015-11-30 |
| US20220135668A1 (en) | 2022-05-05 |
| US20160060337A1 (en) | 2016-03-03 |
| PH12015502129A1 (en) | 2016-01-25 |
| AU2020270495A1 (en) | 2020-12-17 |
| TN2015000403A1 (en) | 2017-01-03 |
| WO2014149425A1 (en) | 2014-09-25 |
| IL275093A (en) | 2020-07-30 |
| JP2016517408A (ja) | 2016-06-16 |
| JP2023011815A (ja) | 2023-01-24 |
| SG11201507482UA (en) | 2015-10-29 |
| CL2015002723A1 (es) | 2016-03-28 |
| PH12019502700A1 (en) | 2020-12-07 |
| CA2906382A1 (en) | 2014-09-25 |
| AU2014238148A1 (en) | 2015-10-08 |
| SG10201804954UA (en) | 2018-07-30 |
| HK1219425A1 (zh) | 2017-04-07 |
| JP2020063237A (ja) | 2020-04-23 |
| EA201591581A1 (ru) | 2016-01-29 |
| AU2019200206A1 (en) | 2019-01-31 |
| AP2015008803A0 (en) | 2015-10-31 |
| CN105209064A (zh) | 2015-12-30 |
| KR20150128858A (ko) | 2015-11-18 |
| EP2968488A1 (en) | 2016-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20150572A (es) | Métodos para tratar la psoriasis utilizando un anticuerpo ant-il-23 | |
| TN2015000402A1 (fr) | Methods for treating crohn's disease using an anti-il23 antibody | |
| MX2017000627A (es) | Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe). | |
| MX2017001512A (es) | Compuestos activos hacia bromodominios. | |
| MX2018002990A (es) | Uso de la akkermansia pasteurizada para tratar trastornos metabolicos. | |
| MX2018011348A (es) | Composiciones de extractos naturales y uso de los mismos para prevenir o tratar enfermedades. | |
| BR112016023362A2 (pt) | molécula de ligação ao antígeno triespecífica | |
| MX2022009538A (es) | Nanoportadores sinteticos tolerogenicos y macromoleculas terapeuticas para efectos farmacodinamicos reducidos o intensificados. | |
| MX390954B (es) | Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo. | |
| BR112018000212A2 (pt) | uso combinado de anticorpos anti pd-1 e anti m-csf no tratamento de câncer | |
| EA201692204A1 (ru) | Композиции и способы модулирования экспрессии фактора комплемента b | |
| MX2017011500A (es) | Combinaciones y formulaciones de dosis fijas que comprenden ácido 8-hidroxi-2,2,14,14- tetrametilpentadecanodioico (etc1002) y una o más estatinas y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
| BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
| CL2016001587A1 (es) | Derivado basado en 1,2-naftoquinona y método de preparación del mismo. | |
| CL2017001756A1 (es) | Régimen de dosificación para antagonistas de madcam. | |
| MX2019010707A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| CL2018003338A1 (es) | Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant. | |
| AR100436A1 (es) | Método y dispositivo para medir la permeabilidad de la dentina | |
| CO2019015102A2 (es) | Nuevos derivados de xantina sustituidos | |
| CO2018013828A2 (es) | Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato | |
| MX2015012455A (es) | Metodo para el tratamiento de la enfermedad de higado graso. | |
| CY1122979T1 (el) | Φαρμακευτικη συνθεση για τη θεραπεια της μυκητιασης | |
| BR112018001793A2 (pt) | preparação cosmética de redução do suor | |
| MX2017003140A (es) | Tratamiento de los sintomas asociados a terapia privacion de androgenos. | |
| BR112016016269A2 (pt) | Formulação de sais de re-hidratação lipossomal |